Baricitinib: First Global Approval.

about

Efficacy of baricitinib in the treatment of rheumatoid arthritis.IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

P2860

Q38652849-FF3B01BE-47A0-48C3-BD7A-2F093AB85FC5 Q47228419-1AB19F48-0C69-4F0F-8C02-7E24D7BD477C Q55163735-680D3858-B265-441A-A99C-8BC2BA093E73

P2860

Baricitinib: First Global Approval.

Item

http://www.wikidata.org/entity/Q39177156

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Baricitinib: First Global Approval.

@en

Baricitinib: First Global Approval.

@nl

type

Item

label

Baricitinib: First Global Approval.

@en

Baricitinib: First Global Approval.

@nl

prefLabel

Baricitinib: First Global Approval.

@en

Baricitinib: First Global Approval.

@nl

P1476

Baricitinib: First Global Approval.

@en

P2093

Anthony Markham

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.

P2888

s40265-017-0723-3

P304

697-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0723-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28290136

http://www.w3.org/2001/XMLSchema#string

Baricitinib: First Global Approval.

about

P2860

P2860

Baricitinib: First Global Approval.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698